Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Surovatamig Plus Rituximab for Untreated Follicular Lymphoma: Initial Safety Data #FL
HealthTreeDescription
Dr. Chan Cheah presents initial safety data from the SOUNDTRACK-F1 Phase 3 trial, studying a new combination therapy for previously untreated follicular lymphoma.
ABOUT THE TRIAL:
The SOUNDTRACK-F1 trial is testing a new drug combination:
- Surovatamig (AZD0486): A newer targeted therapy
- Rituximab: A proven lymphoma treatment
- Patient group: People with follicular lymphoma who haven't received prior treatment
WHY THIS MATTERS:
Rituximab has been used in follicular lymphoma for years. This trial explores whether adding surovatamig could improve results. Initial safety data helps determine if this new combination is safe enough to move forward.
WHAT TO EXPECT:
This is early-stage data focused on safety—which means doctors are primarily looking at side effects and whether patients can tolerate the combination well.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction
0:14 SOUNTRACK-F1 Trial Safety Data
0:43 Response Rates
1:03 Future Trial Plans
#FollicularLymphoma #FL #ClinicalTrial #NewTreatment